NEW YORK, Feb. 8, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657184/Doxil/Caelyx-Ovarian-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary GlobalData's pharmaceuticals report, "Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020" provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Scope - Therapy area profile including patient population for the US, EU and Japan (seven major markets)

- Analysis and review of Doxil/Caelyx including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Doxil/Caelyx including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales estimates for 2002-2020 for Doxil/Caelyx in the seven major markets

Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents1 Table of Contents 21.1 List of Tables 31.2 List of Figures 32 Introduction 42.1 Ovarian Cancer 42.2 Ovarian Cancer Market 42.3 Epidemiology 42.4 Etiology 62.4.1 Age 62.4.2 Inherited Gene Mutations 62.4.3 A Previous Cancer Diagnosis 62.4.4 Early Menstruation or Late menopause 72.4.5 Family History of Ovarian Cancer 72.5 GlobalData Market Forecasts Report Guidance 73 Ovarian Cancer: Market Characterization 83.1 Ovarian Cancer Market 83.2 Ovarian Cancer Market Forecasts and CAGR 83.3 Drivers for Ovarian Cancer Market 93.3.1 High Incidence 93.3.2 High Mortality Rate 103.3.3 Increased Use of Chemotherapy in Ovarian Cancer 113.3.4 Emergence of Targeted Therapy Drugs 113.3.5 Recurrence of Tumor 113.3.6 Low Initial Diagnosis Rate 114 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 125 Doxil 155.1 Introduction 155.2 Mechanism of Action 155.3 Clinical Study 155.4 Approval History of Doxil 155.5 Factors Affecting Sales of Doxil 165.5.1 Supply Constraint 165.5.2 Generics Unavailability 165.5.3 Strong Pipeline 165.6 Drug Evaluation 165.6.1 Drug Risk Benefit Score 165.6.2 Intensity of Competition 175.7 Sales Forecasts 175.7.1 Target Patient Pool of Doxil 175.7.2 Dosing 185.7.3 Market Penetration 185.7.4 Annual Cost of Therapy 195.7.5 Sales Projections of Doxil 206 Ovarian Cancer Market: Appendix 296.1 Market Definitions 296.2 Abberiviations 296.3 Research Methodology 296.3.1 Coverage 296.3.2 Secondary Research 296.3.3 Forecasting 306.3.4 Number of Patients Approved to Take the Drug 306.3.5 Net Penetration of Drug 306.3.6 Net Annual Dosing 306.3.7 Annual Cost of Therapy 306.4 Drug Sales Estimates Model 316.5 Contact Us 316.6 Disclaimer 316.7 Sources 32

List of Tables

Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030 6Table 2: Detailed TNM Classification 13Table 3: Study Details 15Table 4: Approval of Doxil 15Table 5: Drug Risk Benefit Score 16Table 6: Doxil, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2011 19Table 7: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20Table 8: Doxil, Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21Table 9: Doxil, Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020 22Table 10: Doxil, Ovarian Cancer, France, Sales Estimates ($m), 2002-2020 23Table 11: Doxil, Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020 24Table 12: Doxil, Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020 25Table 13: Doxil, Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020 26Table 14: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27

List of Figures Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5

Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030 9

Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030 10

Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030 10

Figure 6: Broad Classification of Ovarian Cancer 12

Figure 7: Classification of Ovarian Cancer 14

Figure 8: Drug Model Diagram of Doxil 18

Figure 9: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020 20

Figure 10: Doxil , Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020 21

Figure 11: Doxil , Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020 22

Figure 12: Doxil , Ovarian Cancer, France, Sales Estimates ($m), 2002-2020 23

Figure 13: Doxil , Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020 24

Figure 14: Doxil , Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020 25

Figure 15: Doxil , Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020 26

Figure 16: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020 27

Figure 17: Doxil, Ovarian Cancer, Global, Sales Distribution (%), 2010 28

Figure 18: Patients Approved for the Drug 30

To order this report:Pathology Industry: Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com